The low and declining risk of malaria in travellers to Latin America: is there still an indication for chemoprophylaxis?
© Behrens et al; licensee BioMed Central Ltd. 2007
Received: 18 June 2007
Accepted: 23 August 2007
Published: 23 August 2007
A comparison was made between local malaria transmission and malaria imported by travellers to identify the utility of national and regional annual parasite index (API) in predicting malaria risk and its value in generating recommendations on malaria prophylaxis for travellers.
Regional malaria transmission data was correlated with malaria acquired in Latin America and imported into the USA and nine European countries. Between 2000 and 2004, most countries reported declining malaria transmission. Highest API's in 2003/4 were in Surinam (287.4) Guyana (209.2) and French Guiana (147.4). The major source of travel associated malaria was Honduras, French Guiana, Guatemala, Mexico and Ecuador. During 2004 there were 6.3 million visits from the ten study countries and in 2005, 209 cases of malaria of which 22 (11%) were Plasmodium falciparum. The risk of adverse events are high and the benefit of avoided benign vivax malaria is very low under current policy, which may be causing more harm than benefit.
Many public health bodies base their recommendations for the prevention of malaria in travellers on national surveillance data, which provides information on the intensity and risk of malaria in local populations, expressed as the annual parasite index (API), which may reflect regional risks. While this approach appears rational, there is no evidence that patterns of travel-acquired malaria correlate with transmission intensity among indigenous populations. Recommendations on prophylaxis for travellers need to balance the threat of malaria, including falciparum malaria, and the risk of a fatal outcome, against the potential toxicity of chemoprophylaxis, a risk which is not relevant to populations living in endemic regions. Rombo called into question the use of API to estimate the risk of travellers acquiring malaria . Highlighting the disparity between native and traveller's vulnerability and exposure to infection he has emphasized the need to consider prophylaxis toxicity when prescribing for travel to low risk malaria regions.
Providing appropriate malaria prophylaxis advice for travellers visiting countries in Central and South America can be complex and challenging, particularly when the journey involves many regions or countries where multiple parasite species are present.
This study was set up to review rates of malaria transmission within Central and South American countries and to compare these with patterns of imported malaria among European and US travellers returned from endemic countries. The aim of the study was to try and identify whether transmission within a country reflects malaria transmission among travellers and to examine the usefulness of API in predicting travellers' risk and its value as a basis for recommendations of malaria prophylaxis.
Regions and Countries from Central and South America included in the destination analysis and countries reporting imported malaria.
C America unspecified
S America unspecified
Reported imported Malaria
United States of America
Malaria risk in Central and South America
Numbers of malaria risk regions in popular tourist destinations, reflecting changing incidence, highest risk regions and species diagnosed during surveillance
Average API's in Moderate and High risk regions
Highest risk regions with total provinces/departments‡
% change API 1998–2004
Highest regional API 2004¥
53.68 (Peten Sur Occidente)
26.55 (Islas de la Bahia)
686.07 (Upper Saramacca)
Low malaria rates were also noted in UK, French and Dutch visitors to Venezuela, Colombia, Peru and Brazil during 2004. These four countries received a total 2.6 million visitors from the study countries (Figure 1) and had a maximum incidence of malaria of 2.2 (UK travellers to Colombia, 2004) per 10,000 visits.
This study was designed to identify whether local transmission of malaria within countries of Latin America reflected the pattern and trends of malaria acquired by travellers from ten developed countries. During 2004, twenty one PAHO countries with active malaria programs examined 6.7 million slides, of which 13% were positive for malaria, three quarters of them were speciated as P. vivax infections in an "at risk" population of 262 million . The detailed information collected in Central and South American countries and presented by PAHO [3, 2, 13] provides evidence of a clear trend of declining transmission across most of the countries, most notably in Brazil, which reported a 56% decrease in the high incidence regions, attributed to malaria control programmes initiated in 2000. The total number of tourists visiting Latin America is not known precisely, but the World Tourism Organization  estimates there were 16 million international tourist arrivals to South America, with a 16% increase from 2003. Central America, during 2004, received 5.7 million inbound visitors, a 17% growth in arrivals over the previous year. The main country sources of imported malaria were Honduras, French Guiana, Guatemala, Mexico and Ecuador, from where there were 1,066 imported cases over five years, accounting for 64% of all imported cases from Latin America, 75% were non-falciparum malaria. There are a number of important limitations that need to be understood when reflecting on the findings. Local transmission reported to PAHO may be inconsistent and regions not reporting or not diagnosing cases may be interpreted as no malaria transmission. The imported malaria cases collected nationally use different reporting methods and are of varied quality. The denominators used in the analysis are again of different capture methods. The USA, France and the Netherlands record the number of citizens departing to a destination while in the UK samples of departing passengers are interviewed, capturing destination, duration of travel and reason for travel. The pattern of travel through the regions by western travellers is not recorded in the denominator data or through the malaria case reports, and therefore the proportion visiting high transmission regions are unknown.
Although a number of regions within Peru and Brazil have an API above 50/1000 cases/year the actual numbers of malaria cases in returning travellers is low, a total of 145 cases over five years, and in 2005, there were only 30 cases of which three were P. falciparum. Asymptomatic carriage in natives living in the Peruvian Amazon near Iquitos is estimated to be less than 10% and the entomological inoculation rate for the Amazonas region reported as 10–20 annually . The small numbers of travel associated cases from Peru are unlikely to be a result of widespread use of chemoprophylaxis. Currie and colleagues  examined prophylaxis use in tourists departing Lima, Peru. Of the 1226 travellers interviewed, 43% were from the USA. Nearly three quarters had visited only Peru and 54% had visited a malarious region (as defined by CDC). Of these around half had taken regular chemoprophylaxis (42% atovaquone/proguanil). During that year (2003) there were 10 (six P vivax) imported malaria cases from Peru. The highest numbers of imported malaria cases, over the 5-year study period, were of P. vivax from Honduras, Guatemala, Ecuador and French Guiana. Despite an increase in local transmission in Honduras, total travel associated cases declined by 20% suggesting that there is no correlation between the two trends. The rates in US and UK travellers to the whole region (excluding Mexico) reveal a similar incidence of 0.3 and 0.8 per 10,000 visits despite an increasing volume of travel over the study (237,526 UK and 4.5 million US travellers in 2005).
Mexico had an estimated 20 million visits by US citizens in 2004. Visits to malaria endemic regions of Mexico are unknown, but are likely to be small. There was a fall in imported malaria to the U.S. from Mexico, from 30 case reports in 2000 to 14 in 2005.
Current chemoprophylaxis policies recommend prophylaxis for high risk regions [20–22], but many of these regions (as shown in Table 2 have a declining risk for indigenous populations). The inconsistency between focal high transmission areas in countries popular with western travellers and small numbers of travel associated malaria is worth exploring. Significant numbers of travellers may not be using prophylaxis during their travel and the departure lounge suggests approximately 50% of visitors will be using chemoprophylaxis. Other countries visited by significant numbers of tourists as reported by WTO in 2005 – Peru, (1.5 million) Brazil (5.4 million), Guatemala (1.3 million) had small numbers of cases and low rates of malaria. Although these countries have areas of high transmission, the major parts of these countries have no malaria transmission. It would appear that most visitors to these countries are at low or no risk of acquiring infection, whatever their journey and destination within the country.
Protection against P. vivax, disease despite using the most widely available regimens is marginal [23–25], as only the primary attack  is aborted. Most clinical episodes develop some months after infection when travellers have returned home and are unlikely to be missed through routine reporting systems. Severe adverse events leading to stopping medication during chemoprophylactic drug use were reported in 3–8% of users whilst mild to moderate adverse events were reported by 32%–45% of users . In the 423,416 visitors from reporting countries to Peru in 2003  approximately 25% (105,000 or 50% of those visiting a malarious region) visitors were using chemoprophylaxis as identified by the airport departure lounge study . During that year, 10 (two P. falciparum) cases of malaria were reported in nine study countries after visiting Peru. Using the minimal proportion of users encountering adverse events from the popular prophylaxis regimens  an estimated 34,000 travellers would have suffered an adverse event related to chemoprophylaxis use. The risk of adverse events for visitors to Peru and other regions are likely to be significantly higher than avoided infections particularly of benign P. vivax malaria under current policy recommendations. Unless chemoprophylaxis prescribing is significantly reduced, current recommendations are likely to be causing more harm than benefit.
Despite its limitations, this study suggests that the risk of adverse events from chemoprophylaxis is likely to be significantly higher than the risk of acquiring malaria in the most popular tourist destinations in Central and South America. Although current national and international policy focuses on chemoprophylaxis for focal, highly endemic malaria transmission regions in countries which have overall low API's, this strategy appears to provide limited benefit as travellers appear to have a low malaria attack rate and will acquire P. vivax rather than P. falciparum infection. The benefit of chemoprophylaxis in preventing the former is unclear. An alternate strategy adopted by a number of European countries, for example Switzerland , is to provide travellers with emergency standby treatment in case of malaria symptoms during travel. This has the benefit of dealing with a life threatening attack of falciparum malaria, but avoiding adverse events associated with excessive chemoprophylaxis. It has the disadvantage of cost, as all travellers will have to purchase therapy. Two of the highest risk countries reported by PAHO – French Guiana, and Surinam, correlated to countries where visitors were at high risk of malaria and chemoprophylaxis would be appropriate for travel to risk areas in these countries. There appears to be no clear benefit and significant potential for toxicity in recommending chemoprophylaxis for visitors to Mexico, where the highest API is less than 0.07 for local residents and 20 imported cases annually. Despite the low or falling risk of malaria, the continued use of bite prevention measures remains important as these are effective, safe and have the added benefit of reducing other vector borne diseases.
USA denominator data: In flight survey ITA Office of Travel & Tourism Industries.
UK cases: Malaria Reference Laboratory, Health Protection Agency UK (Peter Chiodini).
UK denominator data: IPS Office for National Statistics.
France: Centre National de Référence du Paludisme.
Finland: National Public Health Institute, Finland.
Jorge Atouguia, Instituto de Higiene e Medicina Tropical, Lisboa.
Czech Republic National Institute of Public Health in Prague,: C. Benes.
Switzerland: Simone Graf (Swiss Federal Office of Public Health).
Netherlands: National Center of Disease Control Institute for Public Health and the Environment Norway: Section of Infectious Disease Prevention and Control, the Norwegian Institute of Public Health (Hans Blystad).
Jorge Atouguia for translation on information from Brazil and Joaquim Gascon and Rogelio Lopez Velez for information on malaria in Spain. We thank the institutes and persons listed below for providing data for this study.
- Rombo L: Who needs drug prophylaxis against malaria? My personal view. J Travel Med. 2005, 12: 217-221.View ArticlePubMedGoogle Scholar
- PAHO: 44th Directing Council 55th Session of the Regional Committee Status report on Malaria programs in the Americas (Based on 2002 data). 2003, Washington, D.C., USA, CD44/INF/3 (Eng.): 17. [http://www.paho.org/English/AD/DPC/CD/malaria.htm]
- 44th Directing Council 55th Session of the Regional Committee Status report on Malaria programs in the Americas (Based on 2004 data). 2006, [http://www.paho.org/English/AD/DPC/CD/mal-status-2004.pdf]
- Organisation WT: International Tourist Arrivals by Country of Destination. 2006, [http://www.unwto.org/facts/eng/indicators.htm]Google Scholar
- Organization WT: World Tourism Highlights 2006 edition. 2007, [http://www.unwto.org/facts/menu.html]Google Scholar
- Causer LM, Newman RD, Barber AM, Roberts JM, Stennies G, Bloland DVM, Parise ME, Steketee RW: Malaria surveillance--United States, 2000. MMWR Surveill Summ. 2002, 51: 9-21.Google Scholar
- Filler S, Causer LM, Newman RD, Barber AM, Roberts JM, MacArthur J, Parise ME, Steketee RW: Malaria surveillance--United States, 2001. MMWR Surveill Summ. 2003, 52: 1-14.PubMedGoogle Scholar
- Shah S, Filler S, Causer LM, Rowe AK, Bloland PB, Barber AM, Roberts JM, Desai MR, Parise ME, Steketee RW: Malaria surveillance--United States, 2002. MMWR Surveill Summ. 2004, 53: 21-34.PubMedGoogle Scholar
- Eliades MJ, Shah S, Nguyen-Dinh P, Newman RD, Barber AM, Nguyen-Dinh P, Roberts JM, Mali S, Parise ME, Barber AM, Steketee R: Malaria surveillance--United States, 2003. MMWR Surveill Summ. 2005, 54: 25-40.PubMedGoogle Scholar
- Skarbinski J, James EM, Causer LM, Barber AM, Mali S, Nguyen-Dinh P, Roberts JM, Parise ME, Slutsker L, Newman RD: Malaria surveillance--United States, 2004. MMWR Surveill Summ. 2006, 55: 23-37.PubMedGoogle Scholar
- Thwing J, Skarbinski J, Newman RD, Barber AM, Mali S, Roberts JM, Slutsker L, Arguin PM: Malaria surveillance - United States, 2005. MMWR Surveill Summ. 2007, 56: 23-40.PubMedGoogle Scholar
- US Department of Commerce ITA Tourism Industries. 2004 Profile of U.S. Resident Traveler Visiting Overseas Destinations Reported From: Survey of International Air Travelers. ITA. Office of Travel & Tourism Industries, 6 AD, [http://tinet.ita.doc.gov/view/f-2004-11-001/index.html]
- PAHO: Malaria in the Countries and Region of the Americas: Time series Epidemiological Data, 1998-2004. 2006, Pan American Health Organization World Health Organization, [http://www.paho.org/English/AD/DPC/CD/mal-2005.htm]Google Scholar
- Regional Strategic plan for malaria in the Americas 2006 - 2010. 2006, [http://www.paho.org/English/AD/DPC/CD/mal-reg-strat-plan-06.pdf]
- Tourism Market Trends: Americas. Tourism Market Trends. Edited by: Organization WT. 2006, Madrid, Spain, World Tourism Organization, 1-272.Google Scholar
- Verret C, Cabianca B, Haus-Cheymol R, Lafille JJ, Loran-Haranqui G, Spiegel A: Malaria outbreak in troops returning from French Guiana. Emerging Infectious Diseases. 2006, 12: 1794-1795.PubMed CentralView ArticlePubMedGoogle Scholar
- Behrens RH, Bisoffi Z, Björkman A, Gascon J, Hatz CF, Jelinek T, Legros F, Mühlberger N, Voltersvik P: Malaria prophylaxis policy for travellers from Europe to the Indian Sub Continent. Malaria Journal. 2006, 5: 1-7. 10.1186/1475-2875-5-7. [http://www.malariajournal.com/content/5/1/7]View ArticleGoogle Scholar
- Roshanravan B, Kari E, Gilman RH, Cabrera L, Lee E, Metcalfe J, Calderon M, Lescano AG, Montenegro SH, Calampa C, Vinetz JM: Endemic malaria in the Peruvian Amazon region of Iquitos. Am J Trop Med Hyg. 2003, 69: 45-52.PubMedGoogle Scholar
- Currie J, Cabada M, Campos B, Bazan E, Behrens RH, Gotuzzo E: 2005, Lisbon, International Socity of Travel Medicine, Malaria prophylaxis among travelers visiting Peru: Measurement and Analysis of compliance: 2005/5/1. CISTM9,Google Scholar
- CDC: CDC Health Information for International Travel, 2008. 2007, Atlanta, 1-627.Google Scholar
- International Travel and Health: 2007. 2007, Geneva, World Health Organization, 1-227. [http://www.who.int/ith/en/]
- Chiodini PL, Bannister B, Hill DR, Lalloo D, Lea G, Walker E, Whitty CJ: Guidelines for Malaria Prevention in Travellers from the United Kingdom. 2007, [http://www.hpa.org.uk/publications/2006/Malaria/guidelines.htm?submit=Accept]Google Scholar
- E S, Parise M, Kozarsky PE, Cetron M: Delayed onset of malaria - implications for chemoprophylaxis in travelers. N Engl J Med. 2003, 349: 1510-1516. 10.1056/NEJMoa021592.View ArticleGoogle Scholar
- Bottieau E, Clerinx J, Van den EE, Van Esbroeck M, Colebunders R, Van Gompel A, Van den EJ: Imported non-Plasmodium falciparum malaria: a five-year prospective study in a European referral center. Am J Trop Med Hyg. 2006, 75: 133-138.PubMedGoogle Scholar
- Lehky Hagen MR, Haley TJ, Hatz CF: Factors influencing the pattern of imported malaria. J Travel Med. 2005, 12: 72-79.View ArticlePubMedGoogle Scholar
- Schlagenhauf P, Tschopp A, Johnson R, Nothdurft HD, Beck B, Schwartz E, Herold M, Krebs B, Veit O, Allwinn R, Steffen R: Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study. BMJ. 2003, 327: 1078-1081. 10.1136/bmj.327.7423.1078.PubMed CentralView ArticlePubMedGoogle Scholar
- Hatz CF, Beck B, Blum J, Bourquin C, Brenneke F, Funk M, Furrer H, Genton B, Holzer B, Loutan L, Raeber PA, Rudin W, Schlagenhauf P, Steffen R, Stossel U: Supplementum 1: Malariaschutz fur Kurzzeitaufenthalter. Swiss Federal Office of Public Health. 2006, [http://www.bag.admin.ch/themen/medizin/00682/00684/02535/index.html?lang=de]Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.